Want to see AU:CLV full AI Analyst Report?
CLV Stock Chart & Stats
AU$0.88
AU$0.06(6.25%)
At close: 4:00 PM EDT
AU$0.88
AU$0.06(6.25%)
Day’s Range― - ―
52-Week RangeAU$0.53 - AU$1.17
Previous CloseN/A
Volume74.89K
Average Volume (3M)223.73K
Market Cap
AU$160.32M
Enterprise ValueAU$137.95M
Total Cash (Recent Filing)AU$10.27M
Total Debt (Recent Filing)AU$1.26M
Price to Earnings (P/E)18.0
Beta0.06
Next Earnings
Sep 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.08%
Share Statistics
EPS (TTM)0.06
Shares Outstanding166,999,340
10 Day Avg. Volume49,116
30 Day Avg. Volume223,729
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.28
Price to Sales (P/S)1.08
P/FCF Ratio13.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.28Price Target Upside45.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.06
Revenue Forecast (FY)AU$95.30M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & MarginsSustained top-line growth coupled with rising gross and net margins indicates durable demand and improving operational efficiency. Higher margins provide buffer against cost pressure, support reinvestment in products and capacity, and underpin long-term profit resilience across cycles.
Conservative Balance SheetMinimal leverage and a strong equity base give the company financial flexibility to fund capex, R&D and absorb shocks without stressing liquidity. This durable capital structure lowers insolvency risk and supports measured investment or opportunistic M&A over the medium term.
Specialist Product & Business ModelA focus on proprietary dispensing and specialty packaging with contract manufacturing fosters sticky customer relationships and product differentiation. This niche positioning creates structural entry barriers, repeatable revenue streams and pricing leverage in consumer and healthcare segments.
Bears Say
Free Cash Flow DeteriorationA sharp drop in free cash flow growth weakens the company's ability to self-fund expansion, dividends or acquisitions. Even with a decent FCF-to-net-income ratio, such a large decline suggests variability in cash conversion that could constrain strategic spending and heighten refinancing or liquidity risk.
Limited ScaleA small workforce and likely limited manufacturing footprint can constrain operational scale and bargaining power with suppliers and customers. This structural size limit may raise per-unit costs, slow capacity expansion and increase vulnerability to demand swings or single-customer concentration over time.
Modest Return On EquityROE below 10% indicates only moderate efficiency in converting equity into profits. Over the medium term, this may limit compounding of shareholder returns versus higher-return peers, especially if reinvestment is needed to scale the niche business or offset rising costs.
Clover Corporation Limited News
CLV FAQ
What was Clover Corporation Limited’s price range in the past 12 months?
Clover Corporation Limited lowest share price was AU$0.53 and its highest was AU$1.17 in the past 12 months.
What is Clover Corporation Limited’s market cap?
Clover Corporation Limited’s market cap is AU$160.32M.
When is Clover Corporation Limited’s upcoming earnings report date?
Clover Corporation Limited’s upcoming earnings report date is Sep 29, 2026 which is in 54 days.
How were Clover Corporation Limited’s earnings last quarter?
Clover Corporation Limited released its earnings results on Mar 23, 2026. The company reported AU$0.025 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.025.
Is Clover Corporation Limited overvalued?
According to Wall Street analysts Clover Corporation Limited’s price is currently Undervalued.
Does Clover Corporation Limited pay dividends?
Clover Corporation Limited pays a Semiannually dividend of AU$0.01 which represents an annual dividend yield of 2.08%. See more information on Clover Corporation Limited dividends here
What is Clover Corporation Limited’s EPS estimate?
Clover Corporation Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Clover Corporation Limited have?
Clover Corporation Limited has 166,999,340 shares outstanding.
What happened to Clover Corporation Limited’s price movement after its last earnings report?
Clover Corporation Limited reported an EPS of AU$0.025 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 18.725%.
Which hedge fund is a major shareholder of Clover Corporation Limited?
Currently, no hedge funds are holding shares in AU:CLV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Clover Corporation Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.28 (45.45% Upside)
AU$1.28 (45.45% Upside)
Blogger Sentiment
Bullish
AU:CLV Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
24.33%
12-Months-Change
Fundamentals
Return on Equity
2.08%
Trailing 12-Months
Asset Growth
6.81%
Trailing 12-Months
Company Description
Clover Corporation Limited
Clover Corporation Limited engages in the processing and worldwide sale of natural oils, reaching markets across Australia, New Zealand, Asia, Europe, and the Americas. The company's operations also encompass the creation of encapsulated products and extensive research and development focused on functional food and infant nutrition ingredients. Among its principal offerings are Nu-Mega Hi docosahexaenoic tuna oils, designed for use in infant formula and pharmaceutical goods, alongside its Ocean Gold refined tuna oils. Furthermore, it supplies Nu-Mega Driphorm powders, which are incorporated into various infant formulas, follow-on formulas, growing-up milks, and general food products, as well as Nu-Mega Driphorm HA for non-dairy applications. These products cater to several segments, including active living (for immune and sports support), healthy living (benefiting brain and heart health), and the foundational stages of infant and child development. The company, founded in 1988, maintains its corporate headquarters in Altona North, Australia.
CLV Stock 12 Month Forecast
Average Price Target
AU$1.28
▲(45.45% Upside)
Technical Analysis
Noumi Limited
―
Bega Cheese Limited
―
Bioxyne Limited
―
Bubs Australia Ltd.
―
Nutritional Growth Solutions Ltd.
―